Hemophilia
📧 Sign up to get email alerts when something new happens for Hemophilia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2025-07-18Clinical Trial Update: Long-term Follow-up Study of Male Adults With Hemophilia B Previously Treated With Etranacogene Dezaparvovec (CSL222)
A long-term follow-up study of male adults with Hemophilia B previously treated with etranacogene dezaparvovec (CSL222) is enrolling by invi…
-
CLINICAL_TRIALS research · 2025-07-14Clinical Trial Update: Safety, Tolerability, and Efficacy Study of Valoctocogene Roxaparvovec in Hemophilia A With Active or Prior Inhibitors [Phase 1, Phase 2]
This clinical trial update describes safety, tolerability, and efficacy data for valoctocogene roxaparvovec in Hemophilia A patients with in…
-
CLINICAL_TRIALS trial_result · 2025-07-09Clinical Trial Update: A Phase 3 Study of the Safety and Efficacy of Coagulation Factor VIIa (Recombinant) for the Prevention of Excessive Bleeding in Patients With Congenital Hemophilia A or B With Inhibitors to Factor VIII or IX Undergoing Elective Major Surgical Procedures SCOPE HIM [Phase 3]
A Phase 3 trial evaluating recombinant factor VIIa to prevent excessive bleeding in patients with congenital Hemophilia A or B with inhibito…
-
FDA approval · 2025-07-08FDA Approved: HEMLIBRA — Supplemental Application (Genentech, Inc.)
FDA approved a supplemental application for Hemlibra (emicizumab) from Genentech, Inc., updating the labeling to reflect the approved supple…
-
CLINICAL_TRIALS trial_result · 2025-06-25Clinical Trial Update: Comparison of Efficiency of Closed Kinetic Chain Exercises Versus Proprioceptive Exercises Patient With Hemophilia [NA]
This update describes a completed clinical trial comparing closed kinetic chain exercises with proprioceptive exercises in people with Hemop…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-06-24Clinical Trial Update: Isokinetic Strength Training On Functional Performance [NA]
A ClinicalTrials.gov entry evaluating the impact of isokinetic strength training on functional performance in individuals with hemophilia; t…
-
CLINICAL_TRIALS trial_result · 2025-06-15Clinical Trial Update: Study to Learn More About the Physical Activity Level of Patients Suffering From Hemophilia A Treated With Damoctocog Alfa Pegol (LIFE ACTIVE Study)
The LIFE ACTIVE study evaluating physical activity levels in patients with Hemophilia A treated with damoctocog alfa pegol has completed.
-
CLINICAL_TRIALS research · 2025-06-13Clinical Trial Update: Study of the Safety, Pharmacodynamics and Efficacy of ANB-002 in Patients With Hemophilia B (SAFRAN) [Phase 1, Phase 2]
Biocad's ANB-002 is being studied in the SAFRAN Phase 1/2 trial for Hemophilia B and is currently recruiting to evaluate safety, pharmacodyn…
-
CLINICAL_TRIALS trial_result · 2025-06-10Clinical Trial Update: Study of the Efficacy and Safety PF-06741086 in Adult and Teenage Participants With Severe Hemophilia A or Moderately Severe to Severe Hemophilia B [Phase 3]
This document reports the completion of a Phase 3 trial evaluating the efficacy and safety of PF-06741086 in adults and teens with Hemophili…
-
CLINICAL_TRIALS trial_result · 2025-06-05Clinical Trial Update: A Proof-of-concept Study to Reduce Treatment Burden in Haemophilia Participants Receiving Factor VIII and Factor IX Infusions [NA]
This clinical trial update reports a proof-of-concept study aimed at reducing treatment burden for people with hemophilia who receive Factor…
-
EMA withdrawal · 2025-06-04EMA Withdrawn: Beqvez (previously Durveqtix) (fidanacogene elaparvovec) — Pfizer Europe MA EEIG
EMA has withdrawn Beqvez (fidanacogene elaparvovec) for Hemophilia B. The product was previously named Durveqtix and had conditional approva…
-
CLINICAL_TRIALS research · 2025-06-02Clinical Trial Update: An Observational Research Study of the Health of Joints in People With Haemophilia Taking the Medicine Esperoct
An observational study assessing joint health in people with Hemophilia A taking Esperoct, currently recruiting.
-
CLINICAL_TRIALS trial_result · 2025-05-31Clinical Trial Update: A Research Study Investigating Nonacog Beta Pegol (N9-GP) for Treatment and Prevention of Bleedings in Chinese People With Haemophilia B [Phase 3]
Phase 3 trial of Nonacog Beta Pegol (N9-GP) in Chinese patients with Hemophilia B has completed, with results posted for evaluating treatmen…
-
CLINICAL_TRIALS research · 2025-05-18Clinical Trial Update: Effectiveness of an Adapted Physical Activity Program for Subjects Suffering From Haemophilia [NA]
This clinical trial update reports on evaluating an adapted physical activity program for individuals with hemophilia, with recruitment curr…
-
CLINICAL_TRIALS research · 2025-05-07Clinical Trial Update: Predictors of Physical Activity in Adult Patients With Hemophilic Arthropathy
This clinical trial investigates predictors of physical activity in adults with hemophilic arthropathy. The study is not yet recruiting.
-
FDA approval · 2025-05-02FDA Approved: ALHEMO — Supplemental Application (Novo Nordisk)
FDA approved a supplemental application for ALHEMO (Concizumab) from Novo Nordisk, expanding the product's regulatory status.
-
EMA approval · 2025-05-02EMA Authorised: Alprolix (eftrenonacog alfa) — Swedish Orphan Biovitrum AB (publ)
The EMA authorised Alprolix (eftrenonacog alfa) from Swedish Orphan Biovitrum AB (publ) for Hemophilia B. It is designated as an orphan medi…
-
CLINICAL_TRIALS trial_result · 2025-05-01Clinical Trial Update: A Study of Adynovate in Previously Treated Chinese Teenagers and Adults With Severe Hemophilia A [Phase 3]
A Phase 3 trial of Adynovate in previously treated Chinese teenagers and adults with severe Hemophilia A has completed, and the trial result…
-
CLINICAL_TRIALS trial_result · 2025-04-30Clinical Trial Update: The Dynamic Interplay Between Bleeding Phenotype and Baseline Factor Level in Moderate and Mild Hemophilia A and B
Document summarizing a completed AMC-UvA-sponsored trial that investigates how baseline factor levels relate to bleeding phenotype in indivi…
-
CLINICAL_TRIALS trial_result · 2025-04-30Clinical Trial Update: Kinesiophobia in the Parents of Hemophilia Patients
A completed clinical trial evaluating kinesiophobia in the parents of patients with hemophilia and hemophilic arthropathy.
-
CLINICAL_TRIALS trial_result · 2025-04-27Clinical Trial Update: Research Study to Look at How Well the Drug Concizumab Works in Your Body if You Have Haemophilia With Inhibitors [Phase 3]
Phase 3 trial update for Concizumab in people with hemophilia A or B with inhibitors; results have been posted.
-
EMA approval · 2025-04-25EMA Authorised: Elocta (efmoroctocog alfa) — Swedish Orphan Biovitrum AB (publ)
The European Medicines Agency authorised Elocta (efmoroctocog alfa) for Hemophilia A; decision date: 25/04/2025.
-
CLINICAL_TRIALS trial_result · 2025-04-24Clinical Trial Update: A Trial of the Safety and Efficacy of Single-Dose Administration of ANB-010 in Subjects With Hemophilia A [Phase 1, Phase 2]
Biocad reports on a Phase 1/2 study evaluating a single-dose administration of ANB-010 for Hemophilia A. The trial is currently active but n…
-
CLINICAL_TRIALS research · 2025-04-22Clinical Trial Update: Low Dose Emicizumab vs Low Dose Factor VIII in Prophylaxis in Hemophilia A Patients [Phase 2, Phase 3]
A Phase 2/3 clinical trial evaluating low-dose emicizumab compared with low-dose Factor VIII for prophylaxis in Hemophilia A patients. The s…
-
CLINICAL_TRIALS trial_result · 2025-04-18Clinical Trial Update: A Post Approval Commitment Study to Gain More Information on How Safe and Effective KOVALTRY is in Chinese Children, Adolescents /Adults With Severe Hemophilia A [Phase 4]
A Phase 4 post-approval study by Bayer evaluating safety and effectiveness of Kovaltry (octocog alfa) in Chinese children, adolescents, and …